Health care AI company Abridge announces strategic investment from Eli Lilly and a clinical AI partnership with Nvidia to strengthen its position in hospital software.

What happened: Abridge, a health care artificial intelligence company used by hundreds of health systems, announced a strategic investment from pharma giant Eli Lilly and a new collaboration with chipmaker Nvidia to develop what it describes as 'the first foundation model purpose-built for clinical conversations.' The company demonstrated new platform features that document patient visits and offer guidance to clinicians before, during, and after visits.

Why it matters: Abridge is competing in a crowded market for software that supports doctors and streamlines hospital billing and operations. These partnerships with two large companies signal confidence in the company's approach and may help it gain an edge in a field where many vendors are vying for adoption at hospitals and health systems.

What to watch: The success of the new foundation model designed jointly with Nvidia will determine whether Abridge's clinical AI tools deliver measurable value to the hundreds of health systems already using its platform, and whether the partnership accelerates adoption elsewhere in the market.